Patents by Inventor Simon C. Barry

Simon C. Barry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20210038649
    Abstract: The present invention relates to chimeric antigen receptors (CARs) directed to cells expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor. Further provided are methods of targeting neoplastic cells and tumours expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor and methods of treating and preventing cancer is a subject.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Justin T. Coombs, Simon C. Barry, Timothy J. Sadlon
  • CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20190365805
    Abstract: The present invention relates to chimeric antigen receptors (CARs) directed to cells expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor. Further provided are methods of targeting neoplastic cells and tumours expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor and methods of treating and preventing cancer is a subject.
    Type: Application
    Filed: September 10, 2016
    Publication date: December 5, 2019
    Inventors: Justin T. Coombs, Simon C. Barry, Timothy J. Sadlon
  • METHOD FOR OBTAINING TREG-CELLS
    Publication number: 20110123502
    Abstract: A method for generating a population of functional regulatory T cells (TREG-cells), which are a subset of the T cell lineage having the ability to actively suppress immune activation and maintain peripheral immune tolerance, is described. The method comprises the steps of first culturing haemopoietic stem cells (HSC) and/or haemopoietic progenitor cells in the presence of a Notch ligand that supports T cell differentiation, and then isolating T cells having a TREG-cell surface marker phenotype. A suitable source of HSC is cord blood (CB) and a suitable culture medium is OP9 cells engineered to express the Notch Ligand Delta-Like 1 (DL1) (OP9-DL1 cell line). Examples of TREG-cell surface marker phenotypes are CD4+CD25+, CD45RO+, CD45RA+, CD127LOW?, LAG-3 and/or CD39+.
    Type: Application
    Filed: August 30, 2007
    Publication date: May 26, 2011
    Inventors: Simon C. Barry, Richard James D'Andrea, Jonathon F. Hutton